GlassScriptPhysician profile
Camile Ortega
NPI 1598185480
$1,634.32
in general payments reported to CMS, 2019-2025
19 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $89.46 · 2021: $281 · 2022: $303 · 2023: $209 · 2024: $223 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $276.96 | 2019-2024 | Auvi-Q |
| Csl Behring | $229.04 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $218.84 | 2020-2024 | Hyqvia, Cuvitru |
| Grifols USA, LLC | $157.80 | 2021-2025 | Xembify, Gamunex-C |
| Ars Pharmaceuticals Operations, INC. | $147.37 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $80.06 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $77.83 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $68.25 | 2022-2023 | |
| Pharming Healthcare, INC. | $60.07 | 2021-2025 | Ruconest |
| Octapharma USA, INC. | $55.96 | 2021-2023 | Cutaquig |
| Greer Laboratories, INC. | $44.34 | 2019-2025 | Oralair |
| Teva Pharmaceuticals USA, INC. | $41.60 | 2021 | |
| Phadia US INC. | $35.42 | 2021-2022 | |
| Genentech USA, INC. | $30.50 | 2024 | Xolair |
| Leadiant Biosciences, INC. | $28.37 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $25.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.28 | 2024 | Fasenra |
| Chiesi USA, INC. | $18.63 | 2021 | |
| Bio Products Laboratory USA, INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camile Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.